Biomea Fusion (BMEA) Stock Price, News & Analysis

Company Overview

Biomea Fusion, Inc. (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction. BMF-219 is currently undergoing early-phase clinical evaluation in patients with MLL-rearranged leukemias and other malignancies driven by dysregulated menin activity. In parallel, Biomea Fusion is advancing a pipeline of preclinical programs targeting additional epigenetic and chromatin-associated proteins, all developed using its integrated discovery platform.

Founded in 2018, Biomea Fusion has assembled a multidisciplinary team of drug discovery scientists, clinical development experts and regulatory specialists. The company conducts its research and early clinical operations in the United States and is actively exploring collaborations to support later‐stage development and global commercialization. With its focus on epigenetic modulation in oncology, Biomea Fusion seeks to deliver novel treatment options for patients facing unmet medical needs.

Key Stats

• Today's Range: $1.45 to $1.61
• 50-Day Range: $1.51 to $2.67
• 52-Week Range: $1.29 to $12.85
• Volume: 2.88 million shs
• Average Volume: 3.16 million shs
• Market Capitalization: $89.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.50
• Consensus Rating: Moderate Buy

Biomea Fusion Stock Analysis - MarketRank™

Biomea Fusion scored higher than 69% of companies evaluated by MarketBeat, and ranked 310th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Biomea Fusion has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Biomea Fusion has a consensus price target of $9.50, representing about 529.1% upside from its current price of $1.51.

Amount of Analyst Coverage

Biomea Fusion has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biomea Fusion are expected to grow in the coming year, from ($3.93) to ($3.84) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biomea Fusion is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biomea Fusion is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Biomea Fusion has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.54% of the float of Biomea Fusion has been sold short.

Short Interest Ratio / Days to Cover

Biomea Fusion has a short interest ratio ("days to cover") of 5.7.

Change versus previous month

Short interest in Biomea Fusion has recently decreased by 0.90%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biomea Fusion does not currently pay a dividend.

Dividend Growth

Biomea Fusion does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.54% of the float of Biomea Fusion has been sold short.

Short Interest Ratio / Days to Cover

Biomea Fusion has a short interest ratio ("days to cover") of 5.7.

Change versus previous month

Short interest in Biomea Fusion has recently decreased by 0.90%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 0.96

News Sentiment

Biomea Fusion has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Biomea Fusion this week, compared to 3 articles on an average week.

Search Interest

34 people have searched for BMEA on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.

MarketBeat Follows

18 people have added Biomea Fusion to their MarketBeat watchlist in the last 30 days. This is an increase of 64% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biomea Fusion insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.42% of the stock of Biomea Fusion is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.72% of the stock of Biomea Fusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BMEA Stock Analysis - Frequently Asked Questions

How have BMEA shares performed this year?

Biomea Fusion's stock was trading at $3.88 at the start of the year. Since then, BMEA stock has decreased by 61.1% and is now trading at $1.51.

How were Biomea Fusion's earnings last quarter?

Biomea Fusion, Inc. (NASDAQ:BMEA) posted its earnings results on Tuesday, August, 5th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.08.

When did Biomea Fusion IPO?

Biomea Fusion (BMEA) raised $120 million in an initial public offering (IPO) on Friday, April 16th 2021. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler acted as the underwriters for the IPO.

Who are Biomea Fusion's major shareholders?

Top institutional investors of Biomea Fusion include Griffin Asset Management Inc. (0.10%). Insiders that own company stock include Bihua Chen, A2a Pharmaceuticals, Inc and Michael JM Hitchcock.
View institutional ownership trends.

How do I buy shares of Biomea Fusion?

Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Biomea Fusion own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biomea Fusion investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 10/19/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BMEA
• CIK: 1840439
• Web: www.biomeafusion.com
• Phone: 650-980-9099
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Biomea Fusion: $9.50
• High Price Target: $18.00
• Low Price Target: $3.00
• Potential Upside/Downside: +529.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$138.43 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -243.95%
• Return on Assets: -140.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.68
• Quick Ratio: 3.68

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.42 per share
• Price / Book: 1.06

Miscellaneous

• Outstanding Shares: 59,510,000
• Free Float: 48,547,000
• Market Cap: $89.86 million
• Optionable: Optionable
• Beta: -0.12